AZD4877

DRUG6 trials

Sponsors

AstraZeneca

Conditions

Acute Myelogenous LeukemiaBladder CancerCancerCarcinomaLymphomaNHLNeoplasmsNon-Hodgkin Lymphoma

Phase 1

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

CompletedNCT00389389

AstraZenecaNeoplasms

Start: 2006-09-30End: 2008-10-31Target: 75Updated: 2009-05-01

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

TerminatedNCT00460460

AstraZenecaLymphoma

Start: 2007-03-31End: 2007-08-31Target: 75Updated: 2011-01-25

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

TerminatedNCT00471367

AstraZenecaLymphoma, NHL, Non-Hodgkin Lymphoma

Start: 2007-04-30End: 2008-12-31Target: 44Updated: 2009-09-24

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

TerminatedNCT00486265

AstraZenecaAcute Myelogenous Leukemia

Start: 2007-07-31End: 2009-07-31Updated: 2010-12-21

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

CompletedNCT00613652

AstraZenecaCancer, Carcinoma, Tumors

Start: 2008-01-31End: 2009-06-30Target: 30Updated: 2009-07-21

Phase 2

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

CompletedNCT00661609

AstraZenecaBladder Cancer, Renal Pelvis Cancer, Transitional Cell Bladder Cancer +2

Start: 2008-05-31End: 2009-12-31Updated: 2011-01-12

Related Papers

Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.

2013-01-1831 citations

Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia.

2011-04-1541 citations